These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38045916)

  • 1. The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT-Medicare linked data.
    Du XL; Martinez J; Yamal JM; Simpson LM; Davis BR
    Front Cardiovasc Med; 2023; 10():1272385. PubMed ID: 38045916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
    Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
    PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Developing Alzheimer's Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up.
    Du XL; Simpson LM; Osani MC; Yama JM; Davis BR
    J Alzheimers Dis Parkinsonism; 2022; 12(3):. PubMed ID: 35571234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Piller LB; Ford CE; Davis BR; Nwachuku C; Black HR; Oparil S; Retta TM; Probstfield JL;
    J Clin Hypertens (Greenwich); 2006 Sep; 8(9):649-56; quiz 657-8. PubMed ID: 16957427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
    Puttnam R; Davis BR; Pressel SL; Whelton PK; Cushman WC; Louis GT; Margolis KL; Oparil S; Williamson J; Ghosh A; Einhorn PT; Barzilay JI;
    JAMA Intern Med; 2017 Jan; 177(1):67-76. PubMed ID: 27893045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Davis BR; Kostis JB; Simpson LM; Black HR; Cushman WC; Einhorn PT; Farber MA; Ford CE; Levy D; Massie BM; Nawaz S;
    Circulation; 2008 Nov; 118(22):2259-67. PubMed ID: 19001024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
    Yamal JM; Oparil S; Davis BR; Alderman MH; Calhoun DA; Cushman WC; Fendley HF; Franklin SS; Habib GB; Pressel SL; Probstfield JL; Sastrasinh S;
    J Am Soc Hypertens; 2014 Nov; 8(11):808-19. PubMed ID: 25455006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
    J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
    Juraschek SP; Simpson LM; Davis BR; Beach JL; Ishak A; Mukamal KJ
    Hypertension; 2019 Oct; 74(4):1033-1040. PubMed ID: 31476905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
    Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
    J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.